Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
NCT03297489 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 19
Last updated 2021-10-06
Summary
This pilot clinical trial studies how well intravital microscopy works in evaluating patients with primary peritoneal, fallopian tube, or stage IA-IV ovarian cancer. Intravital microscopic evaluation of tumor blood vessels, blood flow, immune cell interactions, and drug uptake may be eventually visualized and may lead to valuable prognostic information.
Conditions
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
- Stage I Ovarian Cancer
- Stage IA Ovarian Cancer
- Stage IB Ovarian Cancer
- Stage IC Ovarian Cancer
- Stage II Ovarian Cancer
- Stage IIA Ovarian Cancer
- Stage IIB Ovarian Cancer
- Stage IIC Ovarian Cancer
- Stage III Ovarian Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIC Ovarian Cancer
- Stage IV Ovarian Cancer
Interventions
- PROCEDURE
-
Diagnostic Microscopy
Undergo observation via intravital microscopy
- DRUG
-
Fluorescein Sodium Injection
Given IV
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
Sponsors & Collaborators
-
Roswell Park Cancer Institute
lead OTHER
Principal Investigators
-
Emese Zsiros, MD · Roswell Park Cancer Institute
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-11-06
- Primary Completion
- 2021-02-15
- Completion
- 2021-02-15
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT05920798 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00753480 ·Status: SUSPENDED ·Phase: PHASE1
-
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
NCT04701645 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
NCT03245892 ·Status: COMPLETED ·Phase: PHASE1
-
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT05708924 ·Status: TERMINATED ·Phase: PHASE1
-
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00053833 ·Status: TERMINATED ·Phase: PHASE2
-
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00112957 ·Status: COMPLETED ·Phase: PHASE2
-
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02050009 ·Status: WITHDRAWN ·Phase: PHASE1
-
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
NCT06240598 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00003345 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
NCT05276973 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT00588237 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00066729 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
NCT00522301 ·Status: TERMINATED ·Phase: PHASE2
-
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT06342986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT00017017 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02316834 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
NCT00059787 ·Status: COMPLETED ·Phase: PHASE2
-
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
NCT03283943 ·Status: UNKNOWN ·Phase: PHASE1
-
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00079430 ·Status: COMPLETED ·Phase: PHASE1
-
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00004012 ·Status: COMPLETED ·Phase: PHASE2
-
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
NCT00369954 ·Status: WITHDRAWN ·Phase: PHASE2
-
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00006391 ·Status: COMPLETED ·Phase: PHASE1
-
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00003560 ·Status: UNKNOWN ·Phase: PHASE2